{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:27:24Z","timestamp":1648942044349},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.rmr.2017.07.025","type":"journal-article","created":{"date-parts":[[2018,2,4]],"date-time":"2018-02-04T13:50:54Z","timestamp":1517752254000},"page":"465-476","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunoth\u00e9rapie anti-tumorale dans le m\u00e9soth\u00e9liome pleural malin"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Scherpereel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-C.","family":"Willemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Wasielewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Dhalluin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2017.07.025_bib0005","article-title":"The experts\u2019 conference of the Soci\u00e9t\u00e9 de Pneumologie de Langue Fran\u00e7aise (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations","volume":"23","author":"Scherpereel","year":"2006","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.rmr.2017.07.025_bib0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994\u00a0and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.rmr.2017.07.025_bib0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"European Respiratory Society\/European Society of Thoracic Surgeons Task Force. Guidelines of the ERS\/ESTS for management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2017.07.025_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/annonc\/mdv199","article-title":"ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0025","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Surgical and large bore pleural procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial) \u2013 an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure-tract metastases","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0030","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(16)30387-4","article-title":"Prophylactic radiotherapy to prevent procedure-tract metastases","volume":"17","author":"Zalcman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0035","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S1556-0864(15)30351-8","article-title":"Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"J\u00e4nne","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2017.07.025_bib0055","doi-asserted-by":"crossref","first-page":"927240","DOI":"10.1155\/2012\/927240","article-title":"New roads open up for implementing immunotherapy in mesothelioma","volume":"2012","author":"Cornelissen","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0060","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint blockade in lung cancer and mesothelioma","author":"Lievense","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2017.07.025_bib0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1\u00a0alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0070","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of BAP1\u00a0accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0075","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1\u00a0function leads to EZ-H2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.rmr.2017.07.025_bib0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Tang","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.rmr.2017.07.025_bib0085","doi-asserted-by":"crossref","first-page":"208ra147","DOI":"10.1126\/scitranslmed.3006941","article-title":"Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression","volume":"5","author":"Hassan","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.rmr.2017.07.025_bib0090","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0095","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.rmr.2017.07.025_bib0100","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0105","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8\u00a0response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2017.07.025_bib0115","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial of immune-gene therapy of malignant pleural mesothelioma using intrapleural delivery of Adenovirus-Interferon-alpha combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0120","doi-asserted-by":"crossref","first-page":"e27482","DOI":"10.4161\/onci.27482","article-title":"Immune checkpoint blockade in malignant mesothelioma: a novel therapeutic strategy against a deadly disease?","volume":"3","author":"Calabr\u00f2","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.rmr.2017.07.025_bib0125","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2\u00a0trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8502","article-title":"Tremelimumab as 2nd- or 3rd-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled DETERMINE study","volume":"34","author":"Kindler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501\u00a0MAPS2\u00a0randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8558","article-title":"Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1\u00a0study","volume":"35","author":"Calabro","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0150","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893\u00a0in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0155","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.1158\/0008-5472.CAN-14-0473","article-title":"Vaccine-elicited CD8+ T-cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment","volume":"74","author":"Tan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0160","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3\u00a0trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rmr.2017.07.025_bib0165","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus Pemetrexed in patients with malignant pleural mesothelioma phase II results from the randomised Placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0170","doi-asserted-by":"crossref","first-page":"492920","DOI":"10.1155\/2012\/492920","article-title":"Modulation of immunity by antiangiogenic molecules in cancer","volume":"2012","author":"Terme","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0175","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2017.07.025_bib0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0185","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1183\/09031936.00081310","article-title":"A 5-aza-2\u2019-deoxycytidine\/valproate combination induces cytotoxic T-cell response against mesothelioma","volume":"38","author":"Leclercq","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2017.07.025_bib0190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.rmr.2017.07.025_bib0195","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","article-title":"PD-L1\u00a0testing for immune checkpoint inhibitors in mesothelioma\u00a0: for want of anything better?","volume":"12","author":"Lantuejoul","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0200","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.rmr.2017.07.025_bib0205","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.rmr.2017.07.025_bib0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.lungcan.2015.08.012","article-title":"Response evaluation in mesothelioma: beyond RECIST","volume":"90","author":"Cheng","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.rmr.2017.07.025_bib0215","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rmr.2017.07.025_bib0220","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00319-2017","article-title":"Malignant pleural mesothelioma: new treatments, new hopes?","volume":"49","author":"Scherpereel","year":"2017","journal-title":"Eur Respir J"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517310264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842517310264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T08:08:37Z","timestamp":1603786117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842517310264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0761842517310264"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2017.07.025","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoth\u00e9rapie anti-tumorale dans le m\u00e9soth\u00e9liome pleural malin","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2017.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 SPLF. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}